- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03375983
Plasmodium Immunotherapy for Advanced Cancers
February 17, 2024 updated by: CAS Lamvac Biotech Co., Ltd.
Clinical Study of Plasmodium Immunotherapy for Advanced Cancers
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is to enroll 20 patients.
Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites and be observed for the exact infection time, parasitemia condition and infection course; principal clinical symptoms such as fever; gastrointestinal reaction; peripheral blood parameters;heart, liver and kidney function; changes in lung function, and dynamic changes in the function of peripheral immune cells.
Moreover, the tolerance of patients to Plasmodium infection and changes in tumor-related parameters will be observed preliminarily.The duration of the planned treatment of each subject is 3-6 months.
Since the successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples, the time of the treatment course is based on the presence of peripheral parasitemia.
After 3-6 months, parasitemia will be terminated by antimalarial drugs for terminating the treatment of Plasmodium immunotherapy ( the immunological treatment effect may persist after the termination of Plasmodium infection).
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Li Qin, M.D
- Phone Number: 0086-18802043960
- Email: njlf@cas-lamvac.com
Study Contact Backup
- Name: Suyi Zhang, M.D
- Phone Number: 0086-20-82258805
- Email: zhang_suyi@cas-lamvac.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Guangzhou Fuda Tumor Hospital
-
Contact:
- Weibing Zhu, M.D.
- Phone Number: 86 20 38993978
- Email: fuda2@fudahospital.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18-70 years of age, male or female.
- Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer, gastric cancer,sarcoma and other solid tumors (except for nasopharyngeal carcinoma, lymphatic cancer, cervical cancer and melanoma).
- The time interval of the termination of chemotherapy (including interventional chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including interventional chemotherapy) or radiotherapy; at least 5 half-life for patients who had received targeted drug therapy (the half-life of targeted drug is according to the drug instructions);
- All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must meet all the remaining requirements that listed in the inclusion criteria;
- ECGO score of 0 or 1;
- Expected survival ≥ 6 months;
- PLT ≥100× 10^9/L, NE ≥ 1.5 × 10^9/L, and HGB ≥ 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.);
- The peripheral blood count of immune cells is close to normal or normal, the immune function test result is close to or at the level of normal population, and the function of heart, lung, liver and kidney are basically normal (the liver function classification of Child-push is A or B, Cr≤1.5×ULN);
- Patient compliance meets the need for follow-up;
- The subjects are able to understand and sign informed consent.
Exclusion Criteria:
- Patients with severe hemoglobin disease or severe G6PD deficiency;
- Patients with splenectomy or splenomegaly;
- Patients with drug addiction or alcohol dependence;
- With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after treatment) and serious or uncontrolled systemic disease or any unstable systemic diseases (including but not limited to active infection, grade three hypertension, unstable angina, congestive heart failure, class III or IV heart disease, severe arrhythmia, liver and kidney dysfunction or metabolic disease), a clear history of neurological or psychiatric disorders, etc;
- Accept any other anti-tumor treatment at the same time;
- Patients with significantly lower immune function than those in the normal population;
- Lung function is seriously damaged, the MNW <39% or can't get out of bed, still feel short of breath when resting;
- Rough cough, dyspnea, without normal diet or difficult to cooperate;
- Poor body condition, the researchers assess that the patients can't tolerate the immune therapy;
- Pregnant or lactating women;
- Women of childbearing age with positive result for pregnancy tests;
- Any condition that makes the subject ineligible to participate (in the opinion of the investigator).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Blood-stage infection of P.vivax
This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites.
And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.
The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
|
The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum.
Exclude other infectious diseases according to the test of national standard of blood donation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0
Time Frame: 2 years
|
Adverse events will be evaluated according to NCI CTCAE 4.0, and the incidence of adverse events will be calculated.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor marker level
Time Frame: 2 years
|
The patient's sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study.
|
2 years
|
Overall survival
Time Frame: 2 years
|
The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death).
|
2 years
|
1 year of survival rate
Time Frame: 2 years
|
The number of cancer cases remaining after 1 year of treatment / the total number of cancer cases treated * 100%.
|
2 years
|
2 year of survival rate
Time Frame: 2 years
|
The number of cancer cases remaining after 2 years of treatment / the total number of cancer cases treated * 100%.
|
2 years
|
Progression free survival
Time Frame: 2 years
|
Progression free survival (PFS): Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions).
|
2 years
|
Objective response rate (ORR)
Time Frame: 2 years
|
The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time.
|
2 years
|
Immunological index
Time Frame: 2 years
|
Detection of absolute number of immune cells(such as CD3+CD4+、CD3+CD8+ and so on )in peripheral blood by flow cytometry.
|
2 years
|
the Score of Quality of life
Time Frame: 2 years
|
Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N, Chen X. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One. 2011;6(9):e24407. doi: 10.1371/journal.pone.0024407. Epub 2011 Sep 9.
- Qin L, Chen C, Chen L, Xue R, Ou-Yang M, Zhou C, Zhao S, He Z, Xia Y, He J, Liu P, Zhong N, Chen X. Worldwide malaria incidence and cancer mortality are inversely associated. Infect Agent Cancer. 2017 Feb 14;12:14. doi: 10.1186/s13027-017-0117-x. eCollection 2017.
- Yang Y, Liu Q, Lu J, Adah D, Yu S, Zhao S, Yao Y, Qin L, Qin L, Chen X. Exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model. Oncogenesis. 2017 Jun 26;6(6):e351. doi: 10.1038/oncsis.2017.52.
- Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L, Chen X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget. 2017 Apr 11;8(15):24785-24796. doi: 10.18632/oncotarget.15806.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 23, 2017
Primary Completion (Actual)
March 31, 2023
Study Completion (Estimated)
July 31, 2026
Study Registration Dates
First Submitted
December 10, 2017
First Submitted That Met QC Criteria
December 15, 2017
First Posted (Actual)
December 18, 2017
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 17, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZKLH-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancers
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
M.D. Anderson Cancer CenterEuropean CommissionCompletedAdvanced CancersUnited States, Spain, France, Israel
-
Aeglea BiotherapeuticsCompletedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterFoundation MedicineCompleted
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterSabinsa CorporationWithdrawnAdvanced Cancers
-
M.D. Anderson Cancer CenterTerminatedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterGateway for Cancer Research; Theravalues, Inc.CompletedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterGE HealthcareWithdrawn
Clinical Trials on Blood-stage infection of P.vivax
-
CAS Lamvac Biotech Co., Ltd.RecruitingAdvanced Breast Cancer | Advanced Liver CancerChina
-
University of OxfordCompleted
-
State Key Laboratory of Respiratory DiseaseCAS Lamvac Biotech Co., Ltd.Recruiting
-
University of OxfordWellcome TrustRecruitingPlasmodium Vivax InfectionThailand
-
University of OxfordCompleted
-
Assiut UniversityNot yet recruiting
-
Clinical Center of VojvodinaCompletedInflammation | Infection | Mediastinitis | Neck Abscess
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Trident Clinical Research Pty Ltd; Queensland Institute...CompletedHealthy | Non-smokersAustralia
-
Fundación Pública Andaluza para la gestión de la...Active, not recruitingCovid19 and PregnancySpain
-
Karolinska University HospitalCompleted